Movatterモバイル変換


[0]ホーム

URL:


CN120242745A - Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof - Google Patents

Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof
Download PDF

Info

Publication number
CN120242745A
CN120242745ACN202510734658.3ACN202510734658ACN120242745ACN 120242745 ACN120242745 ACN 120242745ACN 202510734658 ACN202510734658 ACN 202510734658ACN 120242745 ACN120242745 ACN 120242745A
Authority
CN
China
Prior art keywords
protein
dialysis
bound toxins
solution
plasma transport
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510734658.3A
Other languages
Chinese (zh)
Inventor
黄品同
陈继繁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Second Affiliated Hospital Zhejiang University College Of Medicine
Original Assignee
Second Affiliated Hospital Zhejiang University College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Second Affiliated Hospital Zhejiang University College Of MedicinefiledCriticalSecond Affiliated Hospital Zhejiang University College Of Medicine
Priority to CN202510734658.3ApriorityCriticalpatent/CN120242745A/en
Publication of CN120242745ApublicationCriticalpatent/CN120242745A/en
Pendinglegal-statusCriticalCurrent

Links

Landscapes

Abstract

Translated fromChinese

本发明提供了一种蛋白结合毒素与血浆运输蛋白的分离方法、分离装置及其应用,涉及分离技术领域。本发明提供的蛋白结合毒素与血浆运输蛋白的分离方法,包括:将含有蛋白结合毒素与血浆运输蛋白的溶液进行透析,使得蛋白结合毒素分离至透析膜外;透析过程中对溶液进行超声处理或者超声空化处理。经发明人研究发现,在蛋白结合毒素的透析过程中进行超声或超声空化处理,能够显著促进蛋白结合毒素与血浆运输蛋白的分离,提高蛋白结合毒素的透析效率。该分离方法,简单方便,成本低,能够有效提高蛋白结合毒素的透析效率。

The present invention provides a method for separating protein-bound toxins from plasma transport proteins, a separation device and applications thereof, and relates to the field of separation technology. The method for separating protein-bound toxins from plasma transport proteins provided by the present invention comprises: dialyzing a solution containing protein-bound toxins and plasma transport proteins so that the protein-bound toxins are separated outside the dialysis membrane; and subjecting the solution to ultrasonic treatment or ultrasonic cavitation treatment during the dialysis process. The inventors have found that ultrasonic or ultrasonic cavitation treatment during the dialysis process of protein-bound toxins can significantly promote the separation of protein-bound toxins from plasma transport proteins and improve the dialysis efficiency of protein-bound toxins. The separation method is simple, convenient, low-cost, and can effectively improve the dialysis efficiency of protein-bound toxins.

Description

Separation method and separation device for protein-bound toxin and plasma transport protein and application of separation method and separation device
Technical Field
The invention relates to the technical field of separation, in particular to a separation method and a separation device for protein-bound toxin and plasma transport protein and application thereof.
Background
Patients with advanced chronic kidney disease (uremic phase) have significantly impaired kidney function, resulting in vivo retention of small molecule metabolites due to dysuria. Among them, protein-bound toxins (protein-bound uremic toxins, PBUTs) are mostly products of intestinal bacteria decomposing food proteins, and 96% or more exist in a form of binding with albumin (molecular mass 68000D) in the blood circulation. Common protein binding toxins are indoxyl sulfate (indoxyl sulphate, IS), p-cresol sulfate (p-cresyl sulphate, PCS), hippuric acid (hippuric acid, HA), and the like. PBUTs is gradually considered to be closely related to cardiovascular and cerebrovascular complications, infections, chronic kidney diseases-abnormal mineral and bone metabolism, malnutrition and the like, and is therefore becoming more and more important in clinic.
Conventional hemodialysis does not produce a good removal effect on PBUTs. Clearance of PBUTs in healthy kidneys is largely dependent on tubular secretion, whereas conventional hemodialysis (hemodialysis, HD) mainly mimics the filtration function of the kidneys and only eliminates free toxin fractions. Thus, reducing PBUTs and blood albumin adsorption and increasing PBUTs free fraction are currently the primary methods of enhancing blood-purifying protein-bound toxins.
In view of this, the present invention has been made.
Disclosure of Invention
The first objective of the present invention is to provide a method for separating protein-bound toxins from plasma transport proteins, which solves the above-mentioned problems.
A second object of the present invention is to provide a separation device for protein-bound toxins from plasma transport proteins.
A third object of the present invention is to provide the use of the above-mentioned separation device for protein-bound toxins and plasma transport proteins for the preparation of a product for the treatment of chronic kidney disease.
In order to achieve the above object, the following technical scheme is adopted:
in a first aspect, the present invention provides a method of separating a protein-binding toxin from a plasma transporter, comprising the steps of:
dialyzing the solution containing the protein-bound toxin and the plasma transport protein so that the protein-bound toxin is separated out of the dialysis membrane;
And carrying out ultrasonic treatment or ultrasonic cavitation treatment on the solution in the dialysis process.
As a further technical scheme, the protein-binding toxins include indoxyl sulfate, p-cresol sulfate, and hippuric acid.
As a further aspect, the plasma transporter comprises albumin.
As a further technical solution, the dialysis membrane is used for intercepting plasma transport proteins, and is used for binding toxins through proteins.
As a further technical scheme, the ultrasonic cavitation comprises the following steps:
microbubbles are added to the solution and then sonicated.
As a further technical scheme, the addition amount of the microbubbles is 105-1010/mL.
As a further aspect, the solution comprises blood.
In a second aspect, the invention provides a separation device for protein-bound toxins from plasma transport proteins, comprising a dialysis device and an ultrasound device;
the dialysis device is used for carrying out dialysis treatment on a solution containing protein-bound toxins and plasma transport proteins, so that the protein-bound toxins are separated out of the dialysis membrane;
the ultrasonic device is used for carrying out ultrasonic treatment on the solution in the dialysis device.
As a further technical scheme, the device also comprises a micro-bubble device;
the microbubble device is used for adding the microbubbles to the solution in the dialysis device.
In a third aspect, the invention provides the use of a device for separating a protein-bound toxin from a plasma transport protein as described above in the manufacture of a product for the treatment of chronic kidney disease.
Compared with the prior art, the invention has the following beneficial effects:
The inventor researches find that the ultrasonic treatment or ultrasonic cavitation treatment is carried out in the dialysis process of the protein-bound toxin, so that the separation of the protein-bound toxin and plasma transport protein can be obviously promoted, and the dialysis efficiency of the protein-bound toxin can be improved. The separation method of the protein-bound toxin and the plasma transport protein is simple and convenient, has low cost and can effectively improve the dialysis efficiency of the protein-bound toxin.
Drawings
In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings that are needed in the description of the embodiments or the prior art will be briefly described, and it is obvious that the drawings in the description below are some embodiments of the present invention, and other drawings can be obtained according to the drawings without inventive effort for a person skilled in the art.
FIG. 1 is an ultrasonic cavitation accelerated removal of p-cresol sulfate;
FIG. 2 is an ultrasonic cavitation accelerated removal of indoxyl sulfate.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to embodiments and examples, but it will be understood by those skilled in the art that the following embodiments and examples are only for illustrating the present invention and should not be construed as limiting the scope of the present invention. All other embodiments, which can be made by those skilled in the art based on the embodiments of the invention without making any inventive effort, are intended to be within the scope of the invention. The specific conditions are not specified, and the process is carried out according to conventional conditions or conditions suggested by manufacturers. The reagents or apparatus used were conventional products commercially available without the manufacturer's attention.
Plasma transport proteins are a class of proteins responsible for binding, carrying and transporting specific substances in the blood circulation.
In a first aspect, the present invention provides a method of separating a protein-binding toxin from a plasma transporter, comprising the steps of:
dialyzing the solution containing the protein-bound toxin and the plasma transport protein so that the protein-bound toxin is separated out of the dialysis membrane;
And carrying out ultrasonic treatment or ultrasonic cavitation treatment on the solution in the dialysis process.
The inventor researches find that the non-covalent combination of the plasma transport protein and the protein-binding toxin can be opened by carrying out ultrasonic treatment or ultrasonic cavitation treatment in the dialysis process of the protein-binding toxin, the separation of the protein-binding toxin and the plasma transport protein is promoted, and the dialysis efficiency of the protein-binding toxin is improved. The separation method of the protein-bound toxin and the plasma transport protein is simple and convenient, has low cost and can effectively improve the dialysis efficiency of the protein-bound toxin.
In some alternative embodiments, the protein-binding toxins include, but are not limited to indoxyl sulfate, p-cresol sulfate, and hippuric acid, as well as other protein-binding toxins that are well known to those of skill in the art.
In some alternative embodiments, the plasma transporter includes, but is not limited to, albumin, but may also be other plasma transporters known to those of skill in the art.
In some alternative embodiments, the dialysate is pure water, PBS solution, or commercial dialysate used in clinical hemodialysis, or the like.
In some alternative embodiments, the dialysis membrane is used to entrap plasma transport proteins, permeate proteins, and bind toxins.
In some alternative embodiments, the dialysis membrane has a molecular weight cut-off of 500-10000Da.
In some alternative embodiments, the ultrasonic cavitation comprises the steps of:
Microbubbles (in the present invention, microbubbles refer to bubbles having a particle size of 2 to 8 uM) were added to the solution, followed by ultrasonic treatment.
In some alternative embodiments, the amount of microbubbles added is 105-1010/mL (ultrasonic cavitation can be achieved by the presence of microbubbles in the solution, and the amount of microbubbles added can be selected according to the actual situation).
In some alternative embodiments, the solution comprises blood.
In a second aspect, based on the above separation method, the present invention provides a separation device for protein-bound toxins from plasma transport proteins, comprising a dialysis device and an ultrasound device;
the dialysis device is used for carrying out dialysis treatment on a solution containing protein-bound toxins and plasma transport proteins, so that the protein-bound toxins are separated out of the dialysis membrane;
the ultrasonic device is used for carrying out ultrasonic treatment on the solution in the dialysis device.
The separation device has a simple structure, and can realize the efficient separation of protein-bound toxin and plasma transport protein.
In some alternative embodiments, the protein-binding toxins include, but are not limited to indoxyl sulfate, p-cresol sulfate, and hippuric acid, as well as other protein-binding toxins that are well known to those of skill in the art.
In some alternative embodiments, the plasma transporter includes, but is not limited to, albumin, but may also be other plasma transporters known to those of skill in the art.
In some alternative embodiments, a microbubble device is also included;
the microbubble device is used for adding the microbubbles to the solution in the dialysis device.
In some alternative embodiments, the dialysis device comprises a dialysis bag.
In some alternative embodiments, the ultrasound device comprises an ultrasound illuminator.
In a third aspect, the invention provides the use of a device for separating a protein-bound toxin from a plasma transport protein as described above in the manufacture of a product for the treatment of chronic kidney disease.
The separation device provided by the invention can effectively separate the protein-bound toxin from the plasma transport protein, so that the separation device can be used for dialysis treatment of chronic kidney disease patients.
The invention is further illustrated by the following specific examples and comparative examples, but it should be understood that these examples are for the purpose of illustration only and are not to be construed as limiting the invention in any way.
In the following examples and comparative examples, the 0 time point is the immediate sampling after the dialysate replacement, the 1 time point is the immediate sampling after 10min of the first sampling or 10min of the first ultrasound, the 2 time point is the sampling after 1 hour of dialysis, the 3 time point is the immediate sampling after 10min of continuing dialysis or 10min of the second ultrasound, and the 4 time point is the sampling after 2 hours of dialysis.
Comparative example 1
Solution 1 to be separated was prepared by dissolving 0.66g BSA and 4.52 mg PCS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
And dialyzing the solution 1 to be separated by using a 1000Da filter membrane, sampling liquid outside the dialysis membrane at time points of 0,1, 2,3 and 4 respectively, detecting the sampled liquid by using HPLC, and measuring and calculating the PCS concentration in the dialysis liquid, wherein the result is shown in figure 1. The protein binding rate of PCS in this system was calculated to be 86.7% after 2 hours of dialysis.
Example 1
Solution 1 to be separated was prepared by dissolving 0.66g BSA and 4.52 mg PCS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
The solution 1 to be separated is dialyzed (PBS solution) by a 1000Da filter membrane, ultrasonic irradiation is carried out for 10min at the time points of 0h and 1h, liquid outside the dialysis membrane is sampled at the time points of 0,1, 2, 3 and 4 respectively, the sampled liquid (the solution outside the dialysis membrane) is detected by HPLC, and the PCS concentration in the dialysis liquid is calculated. The results are shown in FIG. 1.
As a result, it was found that the dialysis efficiency of the PCS of example 1 was improved by a factor of 1.68 as compared with comparative example 1.
Example 2
Solution 1 to be separated was prepared by dissolving 0.66g BSA and 4.52 mg PCS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
The solution 1 to be separated is dialyzed (PBS solution) by using a 1000Da filter membrane, microbubbles (the final concentration is 107/mL) are added into the filter membrane, ultrasonic irradiation (the ultrasonic conditions are the same as in the example 1) is carried out for 10min at the time points of 0h and 1h, the liquid outside the dialysis membrane is sampled at the time points of 0, 1, 2,3 and 4 respectively, the sampled liquid (the solution outside the dialysis membrane) is detected by HPLC, and the PCS concentration in the dialysate is calculated. The results are shown in FIG. 1.
As a result, it was found that the dialysis efficiency of the PCS of example 1 was improved by a factor of 3.42 as compared with comparative example 1.
Comparative example 2
Solution 2 to be separated was prepared by dissolving 0.66g of BSA and 2.51 mg IS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
And dialyzing the solution 2 to be separated by using a 1000Da filter membrane, sampling liquid outside the dialysis membrane at time points of 0,1, 2,3 and 4 respectively, detecting the sampled liquid by using HPLC, and measuring and calculating the PCS concentration in the dialysis liquid, wherein the result is shown in figure 2. The protein binding rate of PCS in this system was calculated to be 84.1% after 2 hours of dialysis.
Example 3
Solution 2 to be separated was prepared by dissolving 0.66g of BSA and 2.51 mg IS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
The solution 2 to be separated is dialyzed (PBS solution) by a 1000Da filter membrane, ultrasonic irradiation is carried out for 10min at the time points of 0h and 1h, liquid outside the dialysis membrane is sampled at the time points of 0,1, 2, 3 and 4 respectively, the sampled liquid (the solution outside the dialysis membrane) is detected by HPLC, and the PCS concentration in the dialysis liquid is calculated. The results are shown in FIG. 1.
As a result, it was found that the dialysis efficiency of the PCS of example 1 was improved by 6.1 times as compared with comparative example 1.
Example 4
Solution 2 to be separated was prepared by dissolving 0.66g of BSA and 2.51 mg IS in water, taking the relative ratio of plasma albumin to PBUTs of a patient with chronic renal function as a reference.
The solution 2 to be separated is dialyzed (PBS solution) by using a 1000Da filter membrane, microbubbles (the final concentration is 107/mL) are added into the filter membrane, ultrasonic irradiation (the ultrasonic conditions are the same as in the example 3) is carried out for 10min at the time points of 0h and 1h, the liquid outside the dialysis membrane is sampled at the time points of 0, 1, 2,3 and 4 respectively, the sampled liquid (the solution outside the dialysis membrane) is detected by HPLC, and the PCS concentration in the dialysate is calculated. The results are shown in FIG. 1.
As a result, it was found that the dialysis efficiency of the PCS of example 1 was improved by 11.6 times as compared with comparative example 1.
Experimental studies were performed using BSA with PCS and IS as examples and comparative examples above, and one skilled in the art would reasonably expect that other albumin and protein-bound toxins would also be suitable for isolation by the methods of the present invention based on the results of the present invention.
It should be noted that the above embodiments are merely for illustrating the technical solution of the present invention and not for limiting the same, and although the present invention has been described in detail with reference to the above embodiments, it should be understood by those skilled in the art that the technical solution described in the above embodiments may be modified or some or all of the technical features may be equivalently replaced, and these modifications or substitutions do not make the essence of the corresponding technical solution deviate from the scope of the technical solution of the embodiments of the present invention.

Claims (10)

Translated fromChinese
1.一种蛋白结合毒素与血浆运输蛋白的分离方法,其特征在于,包括以下步骤:1. A method for separating protein-bound toxins from plasma transport proteins, comprising the following steps:将含有蛋白结合毒素与血浆运输蛋白的溶液进行透析,使得蛋白结合毒素分离至透析膜外;dialyzing a solution containing protein-bound toxins and plasma transport proteins to separate the protein-bound toxins outside the dialysis membrane;所述透析过程中对所述溶液进行超声处理或者超声空化处理。During the dialysis process, the solution is subjected to ultrasonic treatment or ultrasonic cavitation treatment.2.根据权利要求1所述的分离方法,其特征在于,所述蛋白结合毒素包括硫酸吲哚酚、硫酸对甲酚和马尿酸。2. The separation method according to claim 1 is characterized in that the protein-bound toxins include indoxyl sulfate, p-cresol sulfate and hippuric acid.3.根据权利要求1所述的分离方法,其特征在于,所述血浆运输蛋白包括白蛋白。3. The separation method according to claim 1, wherein the plasma transport protein comprises albumin.4.根据权利要求1所述的分离方法,其特征在于,所述透析膜用于截留血浆运输蛋白,透过蛋白结合毒素。4. The separation method according to claim 1 is characterized in that the dialysis membrane is used to intercept plasma transport proteins and pass through protein-bound toxins.5.根据权利要求1所述的分离方法,其特征在于,所述超声空化包括以下步骤:5. The separation method according to claim 1, characterized in that the ultrasonic cavitation comprises the following steps:向所述溶液中加入微泡,然后进行超声处理。Microbubbles were added to the solution, followed by sonication.6.根据权利要求5所述的分离方法,其特征在于,所述微泡的加入量为105-1010/mL。The separation method according to claim 5, characterized in that the amount of microbubbles added is 105 -1010 /mL.7.根据权利要求1所述的分离方法,其特征在于,所述溶液包括血液。7. The separation method according to claim 1, characterized in that the solution comprises blood.8.一种蛋白结合毒素与血浆运输蛋白的分离装置,其特征在于,包括透析装置和超声装置;8. A device for separating protein-bound toxins from plasma transport proteins, characterized in that it comprises a dialysis device and an ultrasonic device;所述透析装置用于对含有蛋白结合毒素与血浆运输蛋白的溶液进行透析处理,使得蛋白结合毒素分离至透析膜外;The dialysis device is used to perform dialysis treatment on a solution containing protein-bound toxins and plasma transport proteins, so that the protein-bound toxins are separated outside the dialysis membrane;所述超声装置用于对透析装置内的溶液进行超声处理。The ultrasonic device is used for ultrasonically treating the solution in the dialysis device.9.根据权利要求8所述的分离装置,其特征在于,还包括微泡装置;9. The separation device according to claim 8, further comprising a microbubble device;所述微泡装置用于向透析装置内的溶液中加入微泡。The microbubble device is used to add microbubbles into the solution in the dialysis device.10.权利要求8或9所述的蛋白结合毒素与血浆运输蛋白的分离装置在制备治疗慢性肾脏病的产品中的应用。10. Use of the device for separating protein-bound toxins and plasma transport proteins according to claim 8 or 9 in preparing products for treating chronic kidney disease.
CN202510734658.3A2025-06-042025-06-04 Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereofPendingCN120242745A (en)

Priority Applications (1)

Application NumberPriority DateFiling DateTitle
CN202510734658.3ACN120242745A (en)2025-06-042025-06-04 Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
CN202510734658.3ACN120242745A (en)2025-06-042025-06-04 Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof

Publications (1)

Publication NumberPublication Date
CN120242745Atrue CN120242745A (en)2025-07-04

Family

ID=96179623

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CN202510734658.3APendingCN120242745A (en)2025-06-042025-06-04 Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof

Country Status (1)

CountryLink
CN (1)CN120242745A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5315998A (en)*1991-03-221994-05-31Katsuro TachibanaBooster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
CN101545837A (en)*2009-04-302009-09-30广西师范大学A method for ultrasound dialyzing, a special set for the method and the application of the method
WO2024097706A1 (en)*2022-11-022024-05-10University Of WashingtonSystem for removing protein bound uremic toxins during hemodialysis
CN118001395A (en)*2024-01-252024-05-10浙江大学Carrier for promoting transfection of living cationic lipid-nucleic acid complex by ultrasonic cavitation and preparation method and application thereof
KR20240150863A (en)*2023-04-102024-10-17건양대학교산학협력단Focused ultrasound device for dialyzer

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US5315998A (en)*1991-03-221994-05-31Katsuro TachibanaBooster for therapy of diseases with ultrasound and pharmaceutical liquid composition containing the same
CN101545837A (en)*2009-04-302009-09-30广西师范大学A method for ultrasound dialyzing, a special set for the method and the application of the method
WO2024097706A1 (en)*2022-11-022024-05-10University Of WashingtonSystem for removing protein bound uremic toxins during hemodialysis
KR20240150863A (en)*2023-04-102024-10-17건양대학교산학협력단Focused ultrasound device for dialyzer
CN118001395A (en)*2024-01-252024-05-10浙江大学Carrier for promoting transfection of living cationic lipid-nucleic acid complex by ultrasonic cavitation and preparation method and application thereof

Similar Documents

PublicationPublication DateTitle
ColtonAnalysis of membrane processes for blood purification
Winchester et al.Beta-2 microglobulin in ESRD: an in-depth review
EP2771045B1 (en)Method for the reduction or elimination of one or more components from a blood product
JP4417832B2 (en) Method for removing protein-bound material
JPH07506765A (en) Membrane and method for separating protein-bound substances from protein-containing liquids by dialysis
WO2011131534A1 (en)High cut-off hemodialysis membrane for use in liver dialysis
Shi et al.Increasing the removal of protein‐bound uremic toxins by liposome‐supported hemodialysis
US10625241B2 (en)Hemocompatible adsorber for the dialysis of protein-bound uremic toxins
Tao et al.Enhanced indoxyl sulfate dialyzer clearance with the use of binding competitors
Rodrigues et al.Adsorption-and displacement-based approaches for the removal of protein-bound uremic toxins
CN103524612A (en)Method for separating milk-derived whey proteins in PEG/phosphate aqueous two-phase system
CN109731169A (en) Novel compositions for reducing beta-amyloid in vitro and methods of making the same
US9675746B2 (en)Method and product for blood treatment and purification
WO2019062071A1 (en)Use of liposome in preparing pharmaceutical preparation for removing protein-bound toxin
EP3563888A1 (en)Multi-stage blood purification apparatus for removal of toxins
CN120242745A (en) Method for separating protein-bound toxins from plasma transport proteins, separation device and application thereof
Hestekin et al.High flux novel polymeric membrane for renal applications
Khalil-Manesh et al.Aluminum-Binding Protein in Dialysis Dementia. II. Characterization in Plasma by Ultrafiltration: II. Characterization in Plasma by Ultrafiltration
CN111821263B (en)Liposome, dispersion liquid containing liposome, preparation method and application of liposome and dispersion liquid
CN115998781A (en)Application of birch juice separating liquid in treating gout
Schiffl et al.Beta-2-microglobulin removal by different hemodialysis membranes
CN119930802B (en) A kind of preparation method of lactoferrin
Hoenich et al.A microdomain-structured synthetic high-flux hollow-fiber membrane for renal replacement therapy
CN111956789A (en)Preparation method of nutrient suitable for blood purification patient and nutrient
Gibney et al.The Acute Dialysis Quality Initiative—part I: definitions and reporting of CRRT techniques

Legal Events

DateCodeTitleDescription
PB01Publication
PB01Publication
SE01Entry into force of request for substantive examination
SE01Entry into force of request for substantive examination

[8]ページ先頭

©2009-2025 Movatter.jp